GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

GETI.B

198.6

+2%↑

ATT

102.6

+1.38%↑

AMBEA

130.8

+2.19%↑

ARJOB

26.1

+0.08%↑

MSON.B

11.35

+5.09%↑

Home・Aandelen Lijst・Orexo AB

O
Orexo AB

Gesloten

25.85 1.37

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.1

Max

26.25

Belangrijke statistieken
By Trading Economics
Inkomsten	-68M -116M
Verkoop	-115M 3.3M
EPS	20.884
Winstmarge	-3,503.03
Werknemers	72
EBITDA	-262M -272M

Dividenden
By Dow Jones
Volgende Winsten	28 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-97M 937M
Vorige openingsprijs	24.48
Vorige sluitingsprijs	25.85

Orexo AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mrt 2026, 18:43 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mrt 2026, 17:33 UTC

Acquisities, Fusies, Overnames

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mrt 2026, 23:45 UTC

Marktinformatie

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mrt 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mrt 2026, 23:25 UTC

Marktinformatie

Global Energy Roundup: Market Talk

3 mrt 2026, 22:38 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mrt 2026, 22:16 UTC

Winsten

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mrt 2026, 22:09 UTC

Winsten

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mrt 2026, 22:06 UTC

Winsten

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mrt 2026, 22:05 UTC

Winsten

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mrt 2026, 22:03 UTC

Winsten

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Tech, Media & Telecom Roundup: Market Talk

3 mrt 2026, 21:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

3 mrt 2026, 21:45 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mrt 2026, 21:37 UTC

Winsten

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mrt 2026, 21:26 UTC

Belangrijke Nieuwsgebeurtenissen

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mrt 2026, 20:31 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mrt 2026, 20:04 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mrt 2026, 19:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold and Silver Drop as Energy Surges -- Market Talk

3 mrt 2026, 18:43 UTC

Winsten

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Energy Roundup: Market Talk

3 mrt 2026, 18:29 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mrt 2026, 18:22 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mrt 2026, 18:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mrt 2026, 18:14 UTC

Winsten

How Long Can Anthropic Play Defense? -- WSJ

3 mrt 2026, 17:41 UTC

Belangrijke Nieuwsgebeurtenissen

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mrt 2026, 17:28 UTC

Acquisities, Fusies, Overnames

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Peer Vergelijking

Prijswijziging

Orexo AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.